Literature DB >> 22236003

Cysteine, histidine and glycine exhibit anti-inflammatory effects in human coronary arterial endothelial cells.

S Hasegawa1, T Ichiyama, I Sonaka, A Ohsaki, S Okada, H Wakiguchi, K Kudo, S Kittaka, M Hara, S Furukawa.   

Abstract

The activation of nuclear factor-kappa B (NF-κB) in vascular endothelial cells may be involved in vascular pathogeneses such as vasculitis or atherosclerosis. Recently, it has been reported that some amino acids exhibit anti-inflammatory effects. We investigated the inhibitory effects of a panel of amino acids on cytokine production or expression of adhesion molecules that are involved in inflammatory diseases in various cell types. The activation of NF-κB was determined in human coronary arterial endothelial cells (HCAECs) because NF-κB modulates the production of many cytokines and the expression of adhesion molecules. We examined the inhibitory effects of the amino acids cysteine, histidine and glycine on the induction of NF-κB activation, expression of CD62E (E-selectin) and the production of interleukin (IL)-6 in HCAECs stimulated with tumour necrosis factor (TNF)-α. Cysteine, histidine and glycine significantly reduced NF-κB activation and inhibitor κBα (IκBα) degradation in HCAECs stimulated with TNF-α. Additionally, all the amino acids inhibited the expression of E-selectin and the production of IL-6 in HCAECs, and the effects of cysteine were the most significant. Our results show that glycine, histidine and cysteine can inhibit NF-κB activation, IκBα degradation, CD62E expression and IL-6 production in HCAECs, suggesting that these amino acids may exhibit anti-inflammatory effects during endothelial inflammation.
© 2012 The Authors. Clinical and Experimental Immunology © 2012 British Society for Immunology.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22236003      PMCID: PMC3278693          DOI: 10.1111/j.1365-2249.2011.04519.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  36 in total

1.  The effect of cysteine oxidation on isolated hepatocytes.

Authors:  J Viña; G T Saez; D Wiggins; A F Roberts; R Hems; H A Krebs
Journal:  Biochem J       Date:  1983-04-15       Impact factor: 3.857

2.  Serum levels of soluble adhesion molecules ICAM-1, VCAM-1 and E-selectin in patients with Wegener's granulomatosis.

Authors:  N Ohta; S Fukase; M Aoyagi
Journal:  Auris Nasus Larynx       Date:  2001-11       Impact factor: 1.863

3.  Dietary glycine prevents peptidoglycan polysaccharide-induced reactive arthritis in the rat: role for glycine-gated chloride channel.

Authors:  X Li; B U Bradford; M D Wheeler; S A Stimpson; H M Pink; T A Brodie; J H Schwab; R G Thurman
Journal:  Infect Immun       Date:  2001-09       Impact factor: 3.441

Review 4.  Glycine: a new anti-inflammatory immunonutrient.

Authors:  M D Wheeler; K Ikejema; N Enomoto; R F Stacklewitz; V Seabra; Z Zhong; M Yin; P Schemmer; M L Rose; I Rusyn; B Bradford; R G Thurman
Journal:  Cell Mol Life Sci       Date:  1999-11-30       Impact factor: 9.261

5.  Dietary glycine blunts lung inflammatory cell influx following acute endotoxin.

Authors:  M D Wheeler; M L Rose; S Yamashima; N Enomoto; V Seabra; J Madren; R G Thurman
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2000-08       Impact factor: 5.464

6.  Effect of carnosine and related compounds on the inactivation of human Cu,Zn-superoxide dismutase by modification of fructose and glycolaldehyde.

Authors:  Hiroyuki Ukeda; Yuko Hasegawa; Yumi Harada; Masayoshi Sawamura
Journal:  Biosci Biotechnol Biochem       Date:  2002-01       Impact factor: 2.043

7.  Dietary glycine prevents chemical-induced experimental colitis in the rat.

Authors:  Isao Tsune; Kenichi Ikejima; Miyoko Hirose; Mutsuko Yoshikawa; Nobuyuki Enomoto; Yoshiyuki Takei; Nobuhiro Sato
Journal:  Gastroenterology       Date:  2003-09       Impact factor: 22.682

8.  Pranlukast inhibits NF-kappa B activation in human monocytes/macrophages and T cells.

Authors:  T Ichiyama; S Hasegawa; M Umeda; K Terai; T Matsubara; S Furukawa
Journal:  Clin Exp Allergy       Date:  2003-06       Impact factor: 5.018

9.  An immunoglobulin agent (IVIG) inhibits NF-kappaB activation in cultured endothelial cells of coronary arteries in vitro.

Authors:  T Ichiyama; Y Ueno; H Isumi; A Niimi; T Matsubara; S Furukawa
Journal:  Inflamm Res       Date:  2004-05-12       Impact factor: 4.575

10.  Intravenous immunoglobulin inhibits NF-kappaB activation and affects Fcgamma receptor expression in monocytes/macrophages.

Authors:  Takashi Ichiyama; Yoshiko Ueno; Masanari Hasegawa; Akihiro Niimi; Tomoyo Matsubara; Susumu Furukawa
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-02-25       Impact factor: 3.000

View more
  38 in total

1.  Protein hydrolysate from canned sardine and brewing by-products improves TNF-α-induced inflammation in an intestinal-endothelial co-culture cell model.

Authors:  Elsa F Vieira; John Van Camp; Isabel M P L V O Ferreira; Charlotte Grootaert
Journal:  Eur J Nutr       Date:  2017-07-17       Impact factor: 5.614

2.  Cysteinyl-glycine reduces mucosal proinflammatory cytokine response to fMLP in a parenterally-fed piglet model.

Authors:  Matthew G Nosworthy; Janet A Brunton
Journal:  Pediatr Res       Date:  2016-04-07       Impact factor: 3.756

3.  NMR based serum metabolomics reveals a distinctive signature in patients with Lupus Nephritis.

Authors:  Anupam Guleria; Avadhesh Pratap; Durgesh Dubey; Atul Rawat; Smriti Chaurasia; Edavalath Sukesh; Sanat Phatak; Sajal Ajmani; Umesh Kumar; Chunni Lal Khetrapal; Paul Bacon; Ramnath Misra; Dinesh Kumar
Journal:  Sci Rep       Date:  2016-10-14       Impact factor: 4.379

4.  Hookworm-Derived Metabolites Suppress Pathology in a Mouse Model of Colitis and Inhibit Secretion of Key Inflammatory Cytokines in Primary Human Leukocytes.

Authors:  Phurpa Wangchuk; Catherine Shepherd; Constantin Constantinoiu; Rachael Y M Ryan; Konstantinos A Kouremenos; Luke Becker; Linda Jones; Geraldine Buitrago; Paul Giacomin; David Wilson; Norelle Daly; Malcolm J McConville; John J Miles; Alex Loukas
Journal:  Infect Immun       Date:  2019-03-25       Impact factor: 3.441

Review 5.  The Genetic Architecture of Coronary Artery Disease: Current Knowledge and Future Opportunities.

Authors:  Jaana Hartiala; William S Schwartzman; Julian Gabbay; Anatole Ghazalpour; Brian J Bennett; Hooman Allayee
Journal:  Curr Atheroscler Rep       Date:  2017-02       Impact factor: 5.113

6.  l-Cysteine augments microtubule-associated protein 2 levels and enhances antioxidant activity in rats following traumatic brain injury.

Authors:  Zhu Ouyang; Ganqiong Xu; Yugang Jiang
Journal:  3 Biotech       Date:  2019-06-22       Impact factor: 2.406

7.  Interleukin-33/ST2 Axis as Potential Biomarker and Therapeutic Target in Kawasaki Disease.

Authors:  Seigo Okada; Hiroki Yasudo; Yuji Ohnishi; Chie Matsuguma; Reiji Fukano; Takahiro Motonaga; Takako Waniishi; Shunji Hasegawa
Journal:  Inflammation       Date:  2022-10-08       Impact factor: 4.657

8.  Histidine supplementation improves insulin resistance through suppressed inflammation in obese women with the metabolic syndrome: a randomised controlled trial.

Authors:  R N Feng; Y C Niu; X W Sun; Q Li; C Zhao; C Wang; F C Guo; C H Sun; Y Li
Journal:  Diabetologia       Date:  2013-01-30       Impact factor: 10.122

9.  Serum Metabolomic Signatures Can Predict Subclinical Atherosclerosis in Patients With Systemic Lupus Erythematosus.

Authors:  Kirsty E Waddington; George A Robinson; Leda Coelewij; Elvira Chocano; Thomas McDonnell; Filipa Farinha; Junjie Peng; Pierre Dönnes; Edward Smith; Sara Croca; Jyoti Bakshi; Maura Griffin; Andrew Nicolaides; Anisur Rahman; Elizabeth C Jury; Ines Pineda-Torra
Journal:  Arterioscler Thromb Vasc Biol       Date:  2021-02-04       Impact factor: 10.514

10.  Serum thiols and cardiovascular risk scores: a combined assessment of transsulfuration pathway components and substrate/product ratios.

Authors:  Arduino A Mangoni; Angelo Zinellu; Ciriaco Carru; John R Attia; Marc McEvoy
Journal:  J Transl Med       Date:  2013-04-15       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.